Latest Share Price News

Turnstone Resources has moved A$25,000 of its A$1.1 million placement into the immediately available tranche, reducing the amount still dependent on shareholder approval. The company expects to settle the raising this week, with directors committing A$165,000 to the conditional tranche.

Leeuwin Metals has rejected the possibility of undisclosed exploration results driving a sharp rise in its share price, after ASX queried the move from $0.22 to $0.295. The gold explorer pointed instead to recent Marda news, a company-funded research report, stronger gold prices and buying by a substantial holder.

Revolver Resources says it knows of no undisclosed information behind a sharp rise in its shares and trading volume. The company pointed only to ongoing work at the Dianne Copper Mine and progress towards a positive Final Investment Decision.

Pacific Current Group has rejected a non-binding offer from Roc Partners, citing valuation and shareholder fairness concerns, while continuing to review a separate proposal from River Capital involving a potential share issuance at $13 per share.

NuEnergy Gas Limited has secured A$3.05 million through a placement to fund early gas sales and production expansion at its Tanjung Enim project, alongside advancing other Indonesian coal bed methane assets.

Mader Group has initiated a $30 million on-market share buy-back, signalling confidence in its valuation and financial strength while maintaining its growth strategy.

First Au Limited has secured a foothold in the Sandstone gold district of Western Australia by acquiring five tenements with substantial historical drilling data, aiming to fast-track a maiden JORC-compliant Mineral Resource.

Maronan Metals appoints experienced mining executive Andrew Graham as Managing Director and CEO, marking a key leadership transition to advance its Maronan Project through drilling and feasibility milestones.

Actinogen Medical (ASX:ACW) has clarified that no undisclosed information explains recent unusual trading in its shares, pointing instead to recent underwriting of options and published updates. The biotech also reaffirmed compliance with ASX rules and provided a detailed update on its lead Alzheimer’s drug Xanamem and ongoing clinical trials.

Impact Minerals (ASX: IPT) has pushed back the deadline for its $4.13 million renounceable rights issue by two days, offering shareholders more time to subscribe and clarifying the value of free attaching options.

Andromeda Metals has secured $3.04 million through a Share Purchase Plan and placement, aiming to advance its High Purity Alumina project and complete a Pre-feasibility study.

Core Energy Minerals (ASX:CR3) has secured $3.025 million through a discounted share placement to fund drilling and resource definition at its Nova Uranium Project in Namibia’s Erongo province.